Absorption of tranexamic acid as a prodrug in healthy volunteers.
The absorption of trans-4-(aminomethyl)cyclohexanecarboxylic acid (tranexamic acid, Cyklokapron) administered as the prodrug trans-4-(aminomethylcyclohexanecarboxylate hydrochloride (Kabi 2161) was investigated in 3 healthy volunteers. Kabi 2161 was given orally in doses of 1, 2, 3 and 3.5 mmol, respectively, and as a reference a clinical dose of 1.5 g tranexamic acid (9.6 mmol) was administered. At 3 mmol of Kabi 2161 the same maximum plasma concentration of tranexamic acid was obtained as with the reference drug but with Kabi 2161 it appeared earlier. The recovery of tranexamic acid in the urine 0-48 h after administration of Kabi 2161 was 84.7, 82.4, 89.4 and 97.5%, resp., of the increasing doses. For the tranexamic acid 37.0% could be recovered. A similar result was seen in the areas under the plasma concentration-time curves normalized for dose. With Kabi 2161, 13.1, 19.6, 14.4 and 14.3 mg.h/l.mmol were found compared to 8.0 mg.h/l.mmol with tranexamic acid. From these results it was concluded that Kabi 2161 markedly increased the bioavailability of tranexamic acid in man.
Organic Chemistry Department, KabiVitrum Hematology AB, KabiVitrum AB, Stockholm, Sweden.
C M
CM
Svahn
M
M
Schannong
U
U
Stenberg
L
L
Widlund
D000328:Adult; D001682:Biological Availability; D003509:Cyclohexanecarboxylic Acids / Q000493:pharmacokinetics*; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged; D011355:Prodrugs; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics*
D003509:Cyclohexanecarboxylic Acids; D011355:Prodrugs; D014148:Tranexamic Acid